When we excluded the 8 patients with HER2 copy numbers ≤ 2.0 in tumors, the prognostic significance of the genetic alterations was also demonstrated in 19 patients with a HR+ tumor (Additional file 3: Table S3, Figure 2F, P=0.03), but not in the 34 patients with a HR+ or HR- tumor (Additional file 2: Table S2, Figure 2E, P=0.248). This evidence concerns the gene ERBB2 and neoplasm.